Evidence map›Paper›PMID 34335829›Full record

ArticleEvidence-based complementary and alternative medicine : eCAM2021

Exploring the Mechanism of

Fanfan Hou, Yang Liu, YaHsin Cheng, Ni Zhang, Wenpeng Yan, Fang Zhang

Abstract read
In one paragraph

Article in Evidence-based complementary and alternative medicine : eCAM, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Mechanisms Involved in Therapeutic Effects ofBioMed research international · 2024
    Article
  3. Review
  4. Flavonoids fromADMET & DMPK · 2024
    Review
  5. The Mechanism ofToxins · 2023
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Fanfan HouStomatology Hospital, Shanxi Medical University, Taiyuan 030001, China.ORCID https://orcid.org/0000-0003-1571-560X
Yang LiuStomatology Hospital, Shanxi Medical University, Taiyuan 030001, China.
YaHsin ChengDepartment of Physiology, School of Medicine, China Medical University, Taichung, Taiwan.
Ni ZhangStomatology Hospital, Shanxi Medical University, Taiyuan 030001, China.
Wenpeng YanStomatology Hospital, Shanxi Medical University, Taiyuan 030001, China.
Fang ZhangStomatology Hospital, Shanxi Medical University, Taiyuan 030001, China.ORCID https://orcid.org/0000-0002-6527-1165

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background

methodsTraditional Chinese Medicine Systems Pharmacology (TCMSP) database was used to predict the active components in SBG, and putative molecular targets of SBG were identified using the Swiss Target Prediction database. OSCC-related targets were screened by GeneCards, Online Mendelian Inheritance in Man (OMIM), and Therapeutic Target Database (TTD). Then, we established protein-protein interaction (PPI), compound-target-disease (C-T-D), and compound-target-pathway (C-T-P) networks by Cytoscape to identify the main components, core targets, and pharmacological pathways of SBG against OSCC via applying data mining techniques and topological parameters. Metascape database was utilized for Gene Ontology (GO) and pathway enrichment analysis. The potential interaction of the main components with core targets was revealed by molecular docking simulation, and for the correlation between core targets and OSCC prognosis analysis, the Kaplan-Meier Plotter online database was used.

resultsThere were 25 active compounds in SBG and 86 genes targeted by OSCC. A total of 141 signaling pathways were identified, and it was found that the PI3K-Akt signaling pathway may occupy core status in the anti-OSCC system. GO analysis revealed that the primary biological processes were related to apoptosis, proliferation, and migration. Molecular docking results confirmed that core targets of OSCC had a high affinity with the main compounds of SBG.

conclusionOur study demonstrated multicomponent, multitarget, and multipathway characteristics of SBG in the treatment of OSCC and provided a foundation for further drug development research.

Identifiers

PMID34335829
PMCPMC8292061

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.